NCT06764875 2026-03-09A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerAstraZenecaPhase 3 Recruiting840 enrolled
NCT07332533 2026-01-12A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerShanghai JMT-Bio Inc.Phase 2/3 Not yet recruiting490 enrolled